Randox Showcases New All-In-One Solution for Molecular Diagnostics at MEDLAB Middle East 2020
|
By LabMedica International staff writers Posted on 05 Feb 2020 |

Illustration
Randox Biosciences, a part of Randox Laboratories, (Crumlin, UK), showcased its new Vivalytic molecular diagnostic platform at MEDLAB Middle East, the largest medical laboratory exhibition and congress in the Middle East & North Africa (MENA) region.
Vivalytic is the newest offering from Randox Biosciences for the molecular diagnostic industry to test for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform, which is capable of both Hi-Plex and Lo-Plex testing, combines nucleic acid extraction, PCR amplification followed by a suite of detection methods in a fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required, making Vivalytic a unique space-saving, hygienic solution for molecular diagnostic testing.
Randox Biosciences also showcased its Evidence series of immunoassay analyzers that have been developed using its patented Biochip Array Technology, which includes multiplex protein immunoassays and multiplex nucleic acid arrays. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format. Additionally, Randox Quality Control highlighted its newly-launched Infectious Disease Serology Internal Quality Controls, which include Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more. All the samples are provided in a user-friendly, liquid ready-to-use format, thus significantly reducing preparation time and the risk of pipetting errors.
At this year’s MEDLAB Middle East, Randox Laboratories presented its RX series of clinical chemistry analyzers which feature robust hardware combined with intuitive software for ensuring precise and accurate results. Its extensive test menu delivers consolidation and can help to bring testing in house, reducing both costs and time. Additionally, Randox Laboratories showcased its wide range of reagents for advancing biochemistry testing for laboratories, including niche and superior performance assays which cover routine and novel markers. Applications are available detailing instrument-specific settings for the convenient use of Randox reagents on a wide range of clinical chemistry analyzers. Randox Laboratories also highlighted its range of complete QC solutions comprising true third-party controls for a wide range of testing, including molecular infectious diseases, inter-laboratory data management software and the world’s largest international EQA scheme – RIQAS.
Related Links:
Randox Laboratories
Vivalytic is the newest offering from Randox Biosciences for the molecular diagnostic industry to test for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform, which is capable of both Hi-Plex and Lo-Plex testing, combines nucleic acid extraction, PCR amplification followed by a suite of detection methods in a fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required, making Vivalytic a unique space-saving, hygienic solution for molecular diagnostic testing.
Randox Biosciences also showcased its Evidence series of immunoassay analyzers that have been developed using its patented Biochip Array Technology, which includes multiplex protein immunoassays and multiplex nucleic acid arrays. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format. Additionally, Randox Quality Control highlighted its newly-launched Infectious Disease Serology Internal Quality Controls, which include Lyme Disease, ToRCH, EBV, HIV, HAV, HTLV, CMV, VZV and much more. All the samples are provided in a user-friendly, liquid ready-to-use format, thus significantly reducing preparation time and the risk of pipetting errors.
At this year’s MEDLAB Middle East, Randox Laboratories presented its RX series of clinical chemistry analyzers which feature robust hardware combined with intuitive software for ensuring precise and accurate results. Its extensive test menu delivers consolidation and can help to bring testing in house, reducing both costs and time. Additionally, Randox Laboratories showcased its wide range of reagents for advancing biochemistry testing for laboratories, including niche and superior performance assays which cover routine and novel markers. Applications are available detailing instrument-specific settings for the convenient use of Randox reagents on a wide range of clinical chemistry analyzers. Randox Laboratories also highlighted its range of complete QC solutions comprising true third-party controls for a wide range of testing, including molecular infectious diseases, inter-laboratory data management software and the world’s largest international EQA scheme – RIQAS.
Related Links:
Randox Laboratories
Latest MEDLAB 2020 News
- Diagnostica Stago Displays STA Compact Max and STA Satellite Max Analyzers at MEDLAB
- DAS Srl Exhibits Range of Fully Automated Systems at MEDLAB Middle East 2020
- GeneMatrix Promotes Sex and Respiratory Infection Testing Products at MEDLAB
- Mindray Showcases Comprehensive IVD Solutions Portfolio at MEDLAB Middle East 2020
- New Technology that Detects MRSA in 15 Minutes Introduced at MEDLAB Middle East 2020
- Vircell Exhibits Its New VirClia Lotus and qSPEED-OLIGO Systems at MEDLAB
- EKF Diagnostics Displays POC Analyzers for Hemoglobin, HbA1c And Lactate at MEDLAB Middle East
- Erba Mannheim Launches New Electrolyte Analyzer with Maintenance-free Electrodes at MEDLAB 2020
- MEDLAB Middle East 2020 Addresses Future of Laboratory Medicine
Channels
Clinical Chemistry
view channel
Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read moreMolecular Diagnostics
view channel
Breast Cancer-Specific Signatures Link Genome Instability to Outcomes
Genomic instability is a hallmark of cancer, but most genomic analyses have relied on broad signatures shared across multiple malignancies, limiting their precision for individual tumor types.... Read more
Whole-Genome MRD Test Detects Early Recurrence in Muscle-Invasive Bladder Cancer
Bladder cancer is among the most common malignancies in the United States, with about 85,000 new cases each year. The muscle-invasive form accounts for roughly one quarter of diagnoses and carries a high... Read more
Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer
Prostate cancer is the most common cancer in the U.K., with more than 64,000 men diagnosed and 12,000 deaths each year. For the roughly 10,000 men annually with advanced disease, early assessment of treatment... Read more
FDA-Cleared Genomic Profiling Assay Guides Treatment Selection in Solid Tumors
Datar Cancer Genetics (DCG; Nashik, India), a global precision oncology company, has announced that its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumors, CellDx-Tissue, has received U.... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
AI-Powered Multi-Functional Analyzer Wins German Innovation Award
Hematology services are increasingly delivered across distributed care settings, where limited staffing and complex workflows can extend turnaround times. Advanced morphology review still often depends... Read more





.jpg)



